Mass-producible immune cells kill patient-derived colorectal tumors in mice
Researchers at Kobe University have successfully created a subclass of T cells that can be used across patients and reproduceably turned back into those T cells. These cells attack and shrink human patient-derived colorectal cancer tumors implanted in mice, offering potential for future systemic therapy.